Alumis Inc

ALMS

Healthcare|Biotechnology|USA

$28.32

-1.96 (-6.48%)

Tangible Book

$4.06

Clinical Trials (13)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06846541 Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis	Plaque Psoriasis, Psoriasis (PsO)	P3	Active	1,680	RCT, Double-blind	Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
NCT05966480 Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus	SLE	P2	Active	408	RCT, Double-blind	Envudeucitinib, Placebo
NCT05739435 Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis	Plaque Psoriasis	P2	Active	165	RCT, Open-label	envudeucitinib
NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001	Plaque Psoriasis	P3	Completed	862	RCT, Double-blind	Envudeucitinib, Placebo, Apremilast
NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis	Plaque Psoriasis	P3	Completed	912	RCT, Double-blind	Envudeucitinib, Apremilast, Placebo
NCT05600036 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis	Plaque Psoriasis	P2	Completed	228	RCT, Double-blind	ESK-001, Placebo
NCT05953688 POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU	Uveitis Posterior Non-Infectious, Uveitis, Intermediate	P2	Terminated	36	RCT, Double-blind	ESK-001
NCT05431634 Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants	Safety and Tolerability	P1	Completed	49	RCT, Double-blind	Experimental drug: ESK-001
NCT05330858 Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants	Pharmacokinetics	P1	Completed	14	RCT, Open-label	ESK-001, Rabeprazole
NCT07442149 An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005	Healthy Volunteer	P1	Completed	135	RCT, Double-blind	A-005, A-005, Placebo
NCT07378579 An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001	Healthy Volunteer	P1	Completed	52	RCT, Double-blind	ESK-001, Moxifloxacin (400 mg), Placebo
NCT06962774 An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function	Renal Impairment	P1	Completed	16	Single-blind	ESK-001
NCT06952634 An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage	Hepatic Impairment	P1	Completed	32	Open-label	envudeucitinib